Researchers examined if venetoclax—a therapy commonly used in the treatment of acute myelogenous leukemia and chronic lymphocytic leukemia—was associated with an increased risk of opportunistic infections,...
The study findings potentially challenge the conventional wisdom that the risk of Richter transformation would increase as patients with chronic lymphocytic leukemia live longer with novel treatments. This...
Researchers assessed the efficacy of venetoclax-based treatments for patients with relapsed/refractory chronic lymphocytic leukemia. This study was presented at the 65th ASH Annual Meeting & Exposition...
Researchers set out to compare the time until the next treatment in patients with chronic lymphocytic leukemia who are treated with single-agent ibrutinib at a sustained dose of 420 mg/day vs patients who...
A recent phase 3 trial showed that for untreated patients with chronic lymphocytic leukemia, measurable residual disease-directed ibrutinib–venetoclax therapy had superior progression-free survival compared...
The FDA approved pirtobrutinib for adults with either chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy.
A drug that was first approved in 2009 for the treatment of chronic lymphocytic leukemia has now been approved by the FDA to treat relapsing forms of multiple sclerosis.
In a new study that was presented at the 2018 ASCO Annual Meeting, researchers investigated the prevalence of venous thromboembolism in patients with various types of hematologic malignancies, as well as...
In a recent study, researchers evaluated the safety and efficacy of a certain chimeric antigen receptor–modified T cell therapy in patients with chronic lymphocytic leukemia. To see results of the study,...
